Physician profile
Mojtaba Akhtari
NPI 1922286954
$1,817,034.54
in general payments reported to CMS, 2019-2025
48 companies · $481K in 2025
The $481K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $56K · 2021: $128K · 2022: $284K · 2023: $403K · 2024: $418K · 2025: $481K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $989K · Honoraria: $125K · Consulting Fee: $62K · Travel and Lodging: $48K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $47K · Food and Beverage: $30K · Education: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $988,925.83 |
| Honoraria | $125,447.50 |
| Consulting Fee | $62,157.00 |
| Travel and Lodging | $47,861.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $46,575.00 |
| Food and Beverage | $30,317.25 |
| Education | $727.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $440,086.79 | 2019-2025 | Monjuvi, Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $173,028.56 | 2021-2025 | Reblozyl, Abecma |
| Karyopharm Therapeutics INC. | $141,622.91 | 2021-2025 | Xpovio |
| Sobi, INC | $133,096.09 | 2022-2025 | |
| Genzyme Corporation | $99,745.27 | 2019-2025 | |
| Pharmaessentia USA Corporation | $94,173.60 | 2022-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $92,587.50 | 2019-2024 | Vyxeos |
| Pfizer INC. | $74,784.67 | 2019-2025 | |
| Abbvie INC. | $65,293.74 | 2021-2025 | Venclexta |
| Syndax Pharmaceuticals, INC. | $58,171.46 | 2025 | Revuforj |
| Glaxosmithkline, LLC. | $52,749.77 | 2024-2025 | Ojjaara, Blenrep |
| Takeda Pharmaceuticals U.S.A., INC. | $50,958.97 | 2020-2024 | Iclusig |
| Cti Biopharma Corp. | $50,629.69 | 2022-2023 | Vonjo |
| Astellas Pharma US INC | $42,245.37 | 2023-2025 | Xospata, Xtandi |
| Seagen INC. | $37,874.21 | 2019-2025 | Adcetris |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $32,752.64 | 2022-2024 | Rezlidhia, Tavalisse |
| Secura Bio, INC. | $31,548.97 | 2021-2025 | Copiktra |
| Servier Pharmaceuticals LLC | $29,512.06 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $22,743.43 | 2023 | Tazverik |
| Geron Corporation | $22,071.70 | 2024-2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $20,944.58 | 2019-2024 | Pyrukynd |
| Janssen Biotech, INC. | $13,851.51 | 2019-2025 | Imbruvica, Darzalex, Talvey |
| Celgene Corporation | $10,448.72 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Amgen INC. | $6,646.44 | 2019-2023 | Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $4,937.45 | 2022-2023 | Imbruvica, Epkinly |
| Tg Therapeutics, INC. | $3,700.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $2,711.81 | 2020-2024 | |
| Adc Therapeutics America, INC. | $2,411.40 | 2021-2023 | |
| Genmab U.S., INC. | $2,389.45 | 2024-2025 | Epkinly |
| Janssen Scientific Affairs, LLC | $1,260.00 | 2024 | Darzalex |
| Epizyme, INC. | $745.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $350.75 | 2021-2025 | Imfinzi, Calquence, Tagrisso |
| Lilly USA, LLC | $333.38 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Beone Medicines USA, INC. | $149.09 | 2025 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Merck Sharp & Dohme LLC | $91.15 | 2023-2024 | Keytruda, Lynparza |
| Emd Serono, INC. | $68.55 | 2023-2025 | Bavencio |
| Mirati Therapeutics, INC. | $38.16 | 2023 | Krazati |
| Alexion Pharmaceuticals, INC. | $29.44 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $27.43 | 2023 | Libtayo |
| Aveo Pharmaceuticals, INC. | $23.92 | 2023 | Fotivda |
| Taiho Oncology, INC. | $23.78 | 2019 | |
| Daiichi Sankyo INC. | $20.47 | 2023 | Enhertu |
| Stemline Therapeutics INC. | $20.09 | 2023 | Elzonris |
| Bayer Healthcare Pharmaceuticals INC. | $18.30 | 2019 | |
| Dova Pharmaceuticals | $18.27 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mojtaba Akhtari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.